

See “Efficacy and safety of vedolizumab in Crohn’s disease in patients from Asian countries in the GEMINI 2 study” on page 83-94.

Supplementary Table 1. Country-Wise Distribution of Patients in the Asian Countries Subgroup of GEMINI 2 Patients: Induction Phase

Country	Placebo	Vedolizumab (cohort 1)	Vedolizumab (cohort 2)	All
Hong Kong	2	0	0	2
India	10	19	5	34
South Korea	3	12	11	26
Malaysia	1	3	5	9
Singapore	1	0	0	1
Taiwan	0	0	3	3
Total	17	34	24	75

Placebo and vedolizumab (cohort 1) = the groups that were part of the double-blind induction phase (induction intent-to-treat [ITT] population); Vedolizumab (cohort 2) = additional patients were enrolled to meet the maintenance phase sample size requirements and received open-label vedolizumab (Induction safety population only); Vedolizumab combined = all patients that received vedolizumab during the induction phase.